Formycon AG has revised parts of its preliminary financial guidance for fiscal year 2025, narrowing the scale of expected EBITDA losses and lowering its working capital projection while keeping its revenue forecast unchanged.
The company reiterated a revenue expectation of 45 million euros for FY25. At the same time, it updated its profitability outlook to a reported EBITDA loss of 4 million euros and an adjusted EBITDA loss of 2 million euros. These figures mark an improvement versus its earlier preliminary estimates, which had indicated a reported EBITDA loss of 12 million euros and an adjusted EBITDA loss of 7 million euros.
Formycon also trimmed its working capital estimate to roughly 70 million euros, down from a previous forecast of 73 million euros. The company stated that there is no change to the previously communicated impairment for the program referred to as FYB202.
Management plans to publish audited fiscal year results together with the annual report on Tuesday, when it will also provide an outlook for 2026. The release of audited results had been slated for March 26 but was postponed as the company migrated to a new internal financial planning system.
Earlier in March, Formycon had disclosed preliminary revenue of 45 million euros for FY25, a figure below the prior guidance range of 55 million to 65 million euros. The company attributed the revenue shortfall to a slower than anticipated ramp of the FYB202 program and protracted negotiations tied to commercialization and development partnerships, among them discussions related to its Keytruda biosimilar candidate.
Context and next steps
Formycon's tightened EBITDA guidance reduces the magnitude of projected losses for FY25 without altering the topline revenue target. The firm will present audited financial statements and forward guidance when it issues the annual report on Tuesday, at which point investors will see the full audited picture and management's projections for 2026.
- Revenue: Maintained at 45 million euros for FY25.
- EBITDA: Reported loss now expected at 4 million euros; adjusted loss at 2 million euros (previously 12 million and 7 million respectively).
- Working capital: Forecast reduced to about 70 million euros from 73 million euros.
The company has not provided further changes to impairment estimates for the FYB202 asset, and it attributes prior revenue weakness to operational and partnership-timing factors already disclosed.